Ditchcarbon
  • Contact
  1. Organizations
  2. Alkermes
Public Profile
Pharmaceutical Preparation Manufacturing
IE
updated 24 days ago

Alkermes

Company website

Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.

DitchCarbon Score

How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

30

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Alkermes's score of 30 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

52%

Let us know if this data was useful to you

Alkermes's reported carbon emissions

In 2024, Alkermes reported total carbon emissions of approximately 20,000,000 kg CO2e, a reduction from about 25,000,000 kg CO2e in 2023 and 30,000,000 kg CO2e in 2022. The emissions data for 2021 indicates a combined total of about 33,000,000 kg CO2e, comprising approximately 15,045,000 kg CO2e from Scope 1 and about 17,954,000 kg CO2e from Scope 2 emissions. This trend shows a significant decrease in emissions over the past three years. Alkermes has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organization, indicating that it operates independently in its reporting. The company’s emissions per employee have also shown a downward trend, with figures of about 10,000 kg CO2e per employee in 2024, down from approximately 15,000 kg CO2e in 2023 and 2022. This reflects Alkermes's commitment to improving its operational efficiency and reducing its carbon footprint. Overall, Alkermes is making progress in reducing its carbon emissions, although it has yet to establish formal reduction targets or commitments within recognised frameworks.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
13,960,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
-
-
-
Scope 2
17,785,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
-
-
-
Scope 3
-
-
-
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Alkermes's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Alkermes is in IE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Alkermes is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Bayer Pharma AG

DE
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Sarepta Therapeutics

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

PHH Home Loans, LLC

US
•
Financial intermediation services, except insurance and pension funding services (65)
Updated about 1 month ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251028.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy